A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Part of paid clinical trials in Los Angeles, California.

Sponsor
Hoffmann-La Roche
Study ID
NCT07223697
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Afimkibart — DRUG
    Afimkibart SC injection will be administered as per the schedule defined in the protocol.

Study Details

This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

Key Dates

First listed
Nov 3, 2025
Start date
Jan 8, 2026
Status verified
Aug 2026
Primary completion
Mar 1, 2033
Completion
Mar 1, 2033

Study Design

Enrollment
120 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Afimkibart Group I
    Participants will receive Afimkibart as subcutaneous (SC) injection.
  • Experimental: Afimkibart Group II
    Participants will receive Afimkibart as SC injection.

Primary Outcome Measure

Percentage of Participants with Adverse Events [ Time Frame: From Baseline up to 6 years ]

Central Contacts

  • Reference Study ID Number: CS45943 https://forpatients.roche.com/ No attachments to email below.
    888-662-6728 (U.S. Only)
    [email protected]
  • Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Locations (5)

FacilityCityStateZIPSite coordinators
UCLA Division of DermatologyLos AngelesCalifornia90024-
Olympian Clinical ResearchTampaFlorida33615-
Hamilton Research, LLCAlpharettaGeorgia30022-
Revival Research Institute, LLCTroyMichigan48084-
Best Skin Research LLCCamp HillPennsylvania17011-

Find similar trials in Los Angeles, CA

Nationwide
Atopic dermatitis / eczema trialsDermatology trialsRheumatology trialsAutoimmune disease trials
By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
UCLA Division of Dermatology· Los Angeles, CAOlympian Clinical Research· Tampa, FLHamilton Research, LLC· Alpharetta, GARevival Research Institute, LLC· Troy, MIBest Skin Research LLC· Camp Hill, PA

Related Studies